Non–small cell lung cancer and immune checkpoint inhibitor therapy: Does non-alcoholic fatty liver disease have an effect?

Efficacy and safety of maintenance immune checkpoint inhibitors with or without pemetrexed in advanced non-squamous non-small cell lung cancer: A retrospective study

9 p | 7 | 3

Phase II study of carboplatin/nab-paclitaxel/ atezolizumab combination therapy for advanced nonsquamous non–small cell lung cancer patients with impaired renal function: RESTART trial

5 p | 9 | 3

Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC)

16 p | 15 | 2

Trends in treatment patterns and survival outcomes in advanced non-small cell lung cancer: A Canadian population-based real-world analysis

12 p | 5 | 2

A text-mining approach to study the real-world effectiveness and potentially fatal immune-related adverse events of PD-1 and PD-L1 inhibitors in older patients with stage III/IV non-small cell lung cancer

12 p | 5 | 1

Modulation of chemoimmunotherapy efficacy in non-small cell lung cancer by sex and histology: A real-world, patient-level analysis

8 p | 14 | 1

Clinical implications of bronchoscopy for immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer

8 p | 6 | 1

Altered PD-L1 expression in non-small cell lung cancer patient after induction chemotherapy: A case report

4 p | 0 | 0

Dissociated responses at initial computed tomography evaluation is a good prognostic factor in non-small cell lung cancer patients treated with antiprogrammed cell death-1/ligand 1 inhibitors

8 p | 15 | 0